InvestorPlace - Stock Market News, Stock Advice & Trading Tips One of the questions I get more than any other is, “Jonathan, how do you ...

Vertex Pharmaceuticals is buying an endocrine treatment specialist for $10 billion.

Incyte and TG Therapeutics are seeing strong share growth, backed up by booming revenue and earnings.

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

PJP delivered stronger 5-year returns with lower volatility, while FBT offers broader biotech exposure at a slightly cheaper cost.

Michael Yee, UBS biotech analyst, joins 'The Exchange' to discuss Yee's thoughts on biotech stocks, what's driving the ...

It has been a banner year for biotech buyouts, and these are two of the prime targets.

In 2025, biotechnology stocks had their best year since the COVID-19 pandemic, with the market sector’s two major indexes — the SDPR S&P Biotech ETX (NYSE: XBI) and iShares Biotech ETF (NYSE: IBB) — ...

That is a big risk investors take when trying to find the winners and losers within the biotech sector. While we made the ...

Shares of Profusa (PFSA) hit a record low on Thursday, crashing 28% after the biotech company announced its second reverse ...

Intellia's CRISPR pipeline and Omeros's newly approved therapy each bring unique risk and reward profiles, see how their financials and partnerships compare.